<?xml version="1.0" encoding="UTF-8"?>
<ref id="B164-vaccines-08-00224">
 <label>164.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Cavalli</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>De Luca</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Campochiaro</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Della-Torre</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Ripa</surname>
    <given-names>M.</given-names>
   </name>
   <name>
    <surname>Canetti</surname>
    <given-names>D.</given-names>
   </name>
   <name>
    <surname>Oltolini</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Castiglioni</surname>
    <given-names>B.</given-names>
   </name>
   <name>
    <surname>Tassan Din</surname>
    <given-names>C.</given-names>
   </name>
   <name>
    <surname>Boffini</surname>
    <given-names>N.</given-names>
   </name>
   <etal/>
  </person-group>
  <article-title>Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study</article-title>
  <source>Lancet Rheumatol.</source>
  <year>2020</year>
  <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30127-2</pub-id>
 </element-citation>
</ref>
